Sinopharm Group (Germany) Performance
| X2S Stock | EUR 2.29 0.02 0.87% |
The entity has a beta of 0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sinopharm Group's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sinopharm Group is expected to be smaller as well. At this point, Sinopharm Group has a negative expected return of -0.25%. Please make sure to validate Sinopharm Group's potential upside, as well as the relationship between the daily balance of power and day typical price , to decide if Sinopharm Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sinopharm Group Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Dividend Yield | 0.3166 |
Sinopharm |
Sinopharm Group Relative Risk vs. Return Landscape
If you would invest 266.00 in Sinopharm Group Co on December 13, 2024 and sell it today you would lose (37.00) from holding Sinopharm Group Co or give up 13.91% of portfolio value over 90 days. Sinopharm Group Co is producing return of less than zero assuming 1.0111% volatility of returns over the 90 days investment horizon. Simply put, 9% of all stocks have less volatile historical return distribution than Sinopharm Group, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sinopharm Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sinopharm Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sinopharm Group Co, and traders can use it to determine the average amount a Sinopharm Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2457
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | X2S |
Estimated Market Risk
| 1.01 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sinopharm Group is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sinopharm Group by adding Sinopharm Group to a well-diversified portfolio.
Sinopharm Group Fundamentals Growth
Sinopharm Stock prices reflect investors' perceptions of the future prospects and financial health of Sinopharm Group, and Sinopharm Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sinopharm Stock performance.
| Current Valuation | 15.96 B | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.11 X | |||
| Total Debt | 8.42 B | |||
| Total Asset | 335.41 B | |||
About Sinopharm Group Performance
Assessing Sinopharm Group's fundamental ratios provides investors with valuable insights into Sinopharm Group's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sinopharm Group is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Sinopharm Group performance evaluation
Checking the ongoing alerts about Sinopharm Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sinopharm Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sinopharm Group generated a negative expected return over the last 90 days |
- Analyzing Sinopharm Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sinopharm Group's stock is overvalued or undervalued compared to its peers.
- Examining Sinopharm Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sinopharm Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sinopharm Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sinopharm Group's stock. These opinions can provide insight into Sinopharm Group's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sinopharm Stock Analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.